ANNX
Price:
$5.14
Market Cap:
$547.89M
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune, neurodegenerative, and ophthalmic disorders. The company's C1q is an initiating molecule of the classical complement pathway that targets distinct disease processes, such as antibody-mediated autoimmune disease and complement-mediated neurodegeneration. Its product candidates include ANX005, a monoclonal antibody, which is in Phase II/III clinical trials to treat patients with guillain- barré syndrome; Phase II trial in patients with warm autoimmune hemolytic anemia; and Phase II clinical trial for Huntington's disease and amyotrophic lateral sclerosis. The company is also developin...[Read more]
Industry
Biotechnology
IPO Date
2020-07-24
Stock Exchange
NASDAQ
Ticker
ANNX
According to Annexon, Inc.’s latest financial reports and current stock price. The company's current Current Ratio is 17.18. This represents a change of -7.56% compared to the average of 18.58 of the last 4 quarters.
The mean historical Current Ratio of Annexon, Inc. over the last ten years is 13.59. The current 17.18 Current Ratio has changed 12.53% with respect to the historical average. Over the past ten years (40 quarters), ANNX's Current Ratio was at its highest in in the September 2020 quarter at 41.56. The Current Ratio was at its lowest in in the March 2018 quarter at 0.
Average
13.59
Median
11.39
Minimum
1.68
Maximum
33.33
Discovering the peaks and valleys of Annexon, Inc. Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 718.96%
Maximum Annual Current Ratio = 33.33
Minimum Annual Increase = -65.82%
Minimum Annual Current Ratio = 1.68
Year | Current Ratio | Change |
---|---|---|
2023 | 14.72 | 32.64% |
2022 | 11.10 | -2.60% |
2021 | 11.39 | -65.82% |
2020 | 33.33 | 261.94% |
2019 | 9.21 | -32.99% |
2018 | 13.74 | 718.96% |
The current Current Ratio of Annexon, Inc. (ANNX) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
12.40
5-year avg
15.95
10-year avg
13.59
Annexon, Inc.’s Current Ratio is greater than Immix Biopharma, Inc. (3.47), greater than CNS Pharmaceuticals, Inc. (1.82), greater than Hepion Pharmaceuticals, Inc. (1.30), greater than Freeline Therapeutics Holdings plc (1.95), less than AVROBIO, Inc. (26.17), greater than Day One Biopharmaceuticals, Inc. (14.62), greater than Acumen Pharmaceuticals, Inc. (10.43), greater than X4 Pharmaceuticals, Inc. (4.89), greater than Inozyme Pharma, Inc. (7.68), greater than VectivBio Holding AG (9.14), less than IVERIC bio, Inc. (18.63), greater than Blueprint Medicines Corporation (3.32), greater than Amylyx Pharmaceuticals, Inc. (4.55), less than Karuna Therapeutics, Inc. (19.31), greater than Arcus Biosciences, Inc. (5.24), less than Cullinan Oncology, Inc. (24.46), less than Structure Therapeutics Inc. (27.63), less than Relay Therapeutics, Inc. (18.42), greater than Zura Bio Limited (10.36), less than Icosavax, Inc. (18.06), greater than IN8bio, Inc. (1.84), greater than Wave Life Sciences Ltd. (1.90),
Company | Current Ratio | Market cap |
---|---|---|
3.47 | $49.14M | |
1.82 | $7.15M | |
1.30 | $4.62M | |
1.95 | $28.28M | |
26.17 | $5.24M | |
14.62 | $1.38B | |
10.43 | $142.39M | |
4.89 | $57.64M | |
7.68 | $180.51M | |
9.14 | $1.06B | |
18.63 | $5.51B | |
3.32 | $5.98B | |
4.55 | $361.25M | |
19.31 | $12.60B | |
5.24 | $1.35B | |
24.46 | $730.17M | |
27.63 | $1.91B | |
18.42 | $795.07M | |
10.36 | $178.25M | |
18.06 | $769.04M | |
1.84 | $23.02M | |
1.90 | $2.18B |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Annexon, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Annexon, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Current Ratio?
How can you use the Current Ratio?
What is Annexon, Inc.'s Current Ratio?
How is the Current Ratio calculated for Annexon, Inc. (ANNX)?
What is the highest Current Ratio for Annexon, Inc. (ANNX)?
What is the 3-year average Current Ratio for Annexon, Inc. (ANNX)?
What is the 5-year average Current Ratio for Annexon, Inc. (ANNX)?
How does the current Current Ratio for Annexon, Inc. (ANNX) compare to its historical average?